PREreviews de Identification and evaluation of besifloxacin as repurposed antifungal drug in combination with fluconazole against Candida albicans

Aller directement aux détails du preprint Aller directement aux PREreviews

Identification and evaluation of besifloxacin as repurposed antifungal drug in combination with fluconazole against Candida albicans

par Shuvechha Chakraborty, Ameya Pawaskar, Siddhanath Metkari, Taruna Madan et Susan Idicula-Thomas

Publié: 12 mars 2025
Serveur de preprints: bioRxiv
DOI: 10.1101/2025.03.12.642842

Résumé

Emergence of life-threatening fungal infections like systemic candidiasis concurrently with bacterial infections and limitations of current antifungal therapies warrants the discovery of novel inhibitors. We identified besifloxacin (BS), an FDA-approved antibacterial, as a potent antifungal inhibitor. A combination of besifloxacin with fluconazole showed a positive synergy (δ = 29.58) resulting in 80% inhibition of microbial growth. BS was able to reduce the MIC of FLC from 2mg/L to 0.5 mg/L when used in combination. Additionally in murine systemic Candida infection, BS reduced fungal load by 83% in mice kidneys at a dose of 100 mg/kg/day. The findings demonstrated the antifungal potential of BS, proposing its use in combination therapy with fluconazole to combat resistance through alternative mechanisms.

Lire le preprint

1 PREreview

Rédigez un PREreview Demander une PREreview

PREreview par Grace Toolsie Toolsie et al.

Rédigé par Grace Toolsie Toolsie et Brenda Ametepe
Identification and evaluation of besifloxacin as repurposed antifungal drug in combination with fluconazole against Candida albicans
1. Summary and Overall Impression
  …
Lire la PREreview de Grace Toolsie Toolsie et al.